Zai Lab (NASDAQ:ZLAB) announces
positive topline results from the NORA study, the Phase 3 study of
ZEJULA (niraparib) as a maintenance therapy in Chinese patients with
recurrent epithelial ovarian, fallopian tube, or primary peritoneal
cancer who are in a complete or partial response to platinum-based
chemotherapy.
The NORA study randomized 265 patients at 2:1 to
receive ZEJULA or placebo until disease progression. The study met its
primary endpoint of a statistically significant improvement in
progression free survival for patients with ovarian cancer regardless of
their biomarker status.
The safety profile was consistent with what was
observed from the global NOVA study with lower rates of anemia and
thrombocytopenia.
The full results will be presented at an upcoming scientific meeting.
Zai Lab in-licensed rights to ZEJULA from GSK for Mainland China, Hong Kong and Macau.
https://seekingalpha.com/news/3578275-zai-lab-reports-positive-data-phase-3-nora-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.